Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Commercial Deals Strategy

Big Pharma’s Partnering Process: An Insight Into The Nitty-Gritty

Executive Summary

Amid ongoing interest in accessing innovative assets, including those from South Korea, big pharma participants at a recent symposium in Seoul shared the ins and outs of the complex partnering process.

You may also be interested in...



Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence

Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.

Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence

Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.

J&J’s Wu On Nurturing Innovation In Asia

Dong Wu, head of J&J Innovation, Asia Pacific, outlines to Scrip the group’s partnering approach in South Korea and the Asia Pacific in general. He also offers some tips to Korean companies that are keen to pursue global partnerships.

Table

View full table

Related Content

Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Commercial Deals Strategy
Latest Headlines

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout

Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches

Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit

See All
UsernamePublicRestriction

Register

SC099947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By